CN108977537A - Predict the biomarker long-chain non-coding RNA LINC02327 and kit of colon cancer prognosis - Google Patents
Predict the biomarker long-chain non-coding RNA LINC02327 and kit of colon cancer prognosis Download PDFInfo
- Publication number
- CN108977537A CN108977537A CN201810806682.3A CN201810806682A CN108977537A CN 108977537 A CN108977537 A CN 108977537A CN 201810806682 A CN201810806682 A CN 201810806682A CN 108977537 A CN108977537 A CN 108977537A
- Authority
- CN
- China
- Prior art keywords
- linc02327
- colon cancer
- real
- prognosis
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention provides a kind of biomarker long-chain non-coding RNA LINC02327 and kit for predicting colon cancer prognosis, for predicting the prognosis life cycle of colorectal cancer patients.The preparation of the prediction colon cancer prognosis is real-time fluorescence quantitative PCR detection kit, kit, it also include real time fluorescent quantitative SYBR dyestuff, the water without RNA enzyme comprising the specific primer that the specific primer expressed for testing goal gene LINC02327 and reference gene TUBA1A are expressed.The present invention is related with the survival rate of patient by quantitative fluorescent PCR and the survivorship curve analysis LINC02327 for finding colon cancer tissue source, and content is higher, and survival rate is higher.This method helps to improve the postoperative life quality of colorectal cancer patients, works out aftertreatment scheme, improve survival rate, have far-reaching clinical meaning to predict that the prognosis life cycle analysis of colorectal cancer patients provides strong technical support.
Description
Technical field
The invention belongs to biomedicine technical fields, and in particular to the non-volume of biomarker long-chain of prediction colon cancer prognosis
Code RNA LINC02327 and kit.
Background technique
Recently as the continuous improvement of China's Living consumption, the transformation of environmental degradation and life and work mode, I
State male, women colon cancer incidence and mortality show the trend of cumulative year after year, and there are rejuvenation and the state of an illness are multiple
The sign of hydridization, although China's colon cancer morbidity considers the huge population base in China lower than developed countries such as America and Europes,
Colon cancer morbidity number of cases and dead number of cases absolute quantity have been more than European and American developed countries, and statistical data shows that China makes a definite diagnosis within 2005
For 180,000 people of colorectal cancer patients, death toll is up to 100,000.Therefore pay attention to and reinforce the preventing and controlling of colon cancer, understand colon
The clinic and pathological characteristic of cancer, actively carrying out early stage diagnosis of colon cancer has weight to control China's colon cancer morbidity, the death rate
Want meaning.Currently, clinically there are no ideal molecular indexes come the risk assessing prognosis and shift.Therefore, it finds new
Prognosis biomarker be current urgent problem.
Sequence in human genome only less than 2% is protein coding, although other sequences non-coding protein,
RNA can be transcribed into more than 90%.These cannot be referred to as non-coding RNA for the RNA molecule of protein coding.Non-coding RNA
Various biological process is taken part in, and is played a significant role in tumor development.Non-coding RNA is roughly divided into based on scale
Two major classes: short chain non-coding RNA and long-chain non-coding RNA.As the new role in non-coding RNA, long-chain non-coding RNA is each
Important regulating and controlling effect is played in kind disease especially tumour, becomes the hot spot of tumor research.Long-chain non-coding RNA is in a variety of levels
The expression of the controlling genes such as level-off i.e. after epigenetic level, transcriptional level and transcription.A large amount of evidences show that a variety of long-chains are non-
There are unconventionality expressions in multiclass tumour for coding RNA, play rush cancer or cancer suppressing action in the generation, development process of tumour.
In recent years, more and more researches show that the generation of the unconventionality expression of long-chain non-coding RNA and tumour, development and invasion transfer have
Substantial connection.Therefore, explore tumour correlation long-chain non-coding RNA and correlation between protein coding gene at
For the important topic of knubble biological research field.
LINC02327 is a kind of newfound non-coding RNA, and transcript length is greater than 200 nucleotide.Currently,
The important function that LINC02327 is played during normal cell development or tumor development is also in further research.
Whether LINC02327 can be used as the new tumor markers of one kind for predicting that colorectal cancer patients prognosis not yet has been reported that.Therefore,
We illustrate for the first time with LINC02327 is new colon carcinoma marker the feasibility for predicting patient's prognosis.
Summary of the invention
The purpose of the present invention is to provide a kind of biomarker long-chain non-coding RNAs for predicting colon cancer prognosis
LINC02327 and kit, for predicting the prognosis life cycle of colorectal cancer patients.
To achieve the above object, the present invention adopts the following technical scheme: the biomarker of prediction colon cancer prognosis is
Long-chain non-coding RNA LINC02327, the nucleic acid sequence of long-chain non-coding RNA LINC02327 is as shown in SEQ NO:1.
Application of the long-chain non-coding RNA LINC02327 biomarker in the preparation of preparation prediction colon cancer prognosis.
The preparation of the prediction colon cancer prognosis is real-time fluorescence quantitative PCR detection kit.
For predicting the real-time fluorescence quantitative PCR detection kit of colon cancer prognosis, comprising being used for testing goal gene
The specific primer of LINC02327 expression, primer sequence are SEQ NO:2 and SEQ NO:3.
For predicting that the real-time fluorescence quantitative PCR detection kit of colon cancer prognosis includes reference gene TUBA1A expression
Specific primer, primer sequence are SEQ NO:4 and SEQ NO:5.
The real-time fluorescence quantitative PCR detection kit for predicting colon cancer prognosis includes real time fluorescent quantitative
SYBR dyestuff, the water without RNA enzyme.
Real time fluorescent quantitative SYBR in the real-time fluorescence quantitative PCR detection kit for predicting colon cancer prognosis
The volume ratio of dyestuff, target gene LINC02327 specific primer, reference gene TUBA1A specific primer, water without RNA enzyme
For 10:1:1:6.
The beneficial effects of the present invention are: the present invention has found colon cancer group by quantitative fluorescent PCR and survivorship curve analysis
The LINC02327 for knitting source is related to the survival rate of patient, and content is higher, and survival rate is higher.This method is prediction colorectal cancer patients
Prognosis life cycle analysis provide strong technical support, help to improve the postoperative life quality of colorectal cancer patients, make
Aftertreatment scheme is ordered, survival rate is improved, there is far-reaching clinical meaning.
Detailed description of the invention
Fig. 1 is that real-time fluorescence quantitative PCR analyzes differential expression of the LINC02327 in normal tissue and colon cancer.
The prognosis of the LINC02327 expression height to colorectal cancer patients in the tracing analysis colon cancer tissue source for survival Fig. 2
It influences.
Specific embodiment
Present invention will be further explained below with reference to the attached drawings and specific embodiments.
Embodiment 1
The biomarker for predicting colon cancer prognosis is long-chain non-coding RNA LINC02327, the long-chain non-coding RNA
The nucleic acid sequence of LINC02327 is as shown in SEQ NO:1.
The preparation for predicting colon cancer prognosis is real-time fluorescence quantitative PCR detection kit, real-time fluorescence quantitative PCR detection examination
Agent box includes the specific primer for testing goal gene LINC02327 expression, primer sequence such as SEQ NO:2 and SEQ NO:
Shown in 3, real-time fluorescence quantitative PCR detection kit also includes the specific primer of reference gene TUBA1A expression, primer sequence
As shown in SEQ NO:4 and SEQ NO:5.
The reagent of preparation detection LINC02327 expression quantity is used to prepare the kit of colorectal cancer patients prognosis (for 50 times
Reaction), required reagent includes: that 500 μ L of SYBR Green qPCR Mix, 3 μM of target gene LINC02327 specificity are drawn
50 μ L of object, 3 μM of 50 μ L of reference gene TUBA1A specific primer, the 300 μ L of water without RNA enzyme.
Extracted total RNA agents useful for same in the tumour or normal control tissue of colon cancer, comprising: Trizol l20mL, inhibit
RNA degradation solvent 40mL, chloroform 80mL, isopropanol 80mL, DEPC water 10mL.
It by LINC02327 reverse transcription is cDNA agents useful for same, including 10 × random primer and Oligo by template of total serum IgE
100 μ L of mixture, 5 × reverse transcription reaction buffer, 150 μ L, the 10mM of dT primer contain Mg2+Triphosphoric acid base deoxynucleotide
100 μ L of dNTP, 50 μ L of 200U/ μ L M-MLV reverse transcriptase.
Embodiment 2
The detection of tissue samples LINC02327
1, colon cancer tumours tissue or normal control tissue to be measured are collected, after physiological saline cleans up, is put into and fills inhibition RNA
It degrades in the cryopreservation tube of solvent, puts spare to -80 DEG C of refrigerators.
2, the extracting of RNA in organizing
(1) liquid nitrogen is first added in mortar, then tissue is cut into small pieces and is clayed into power in liquid nitrogen, taken with the spoon of Liquid nitrogen precooler
100mg organizes powder to be added in the EP pipe for the Trizol liquid for having filled 1ml.Organize total powder volume no more than Trizol used
The 10% of volume is sufficiently mixed uniformly.
(2) 5 minutes are placed at room temperature for, the chloroform of 200 μ L is then added, EP is covered tightly and manages and acutely sway 0.5 minute.12000
Rev/min centrifugation 10 minutes.
(3) it takes upper strata aqueous phase in a new EP pipe, 500 μ L isopropanols is added, are mildly mixed by inversion.It is placed at room temperature for 10 points
Clock, 12000 revs/min are centrifuged 10 minutes.
(4) liquid is carefully discarded supernatant, 75% ethyl alcohol of 1ml is added, is vortexed and mixes, 12000 revs/min of centrifugations 5 at 4 DEG C
Minute.Repetitive operation is primary.
(5) discard supernatant liquid, as far as possible remove residual liquid, room temperature or vacuum drying 5~10 minutes.With 50 μ L DEPC
Processed water dissolves RNA.
(6) RNA concentration mensuration: being measured with nucleic acid concentration analyzer, is inhaled 1 μ L RNA sample and is added to sample well, according to
Reading directly determines the concentration of RNA.The OD260/OD280 ratio of the measurement of nucleic acid concentration analyzer, ratio is between 1.8-2.0
Think that RNA purity is fine.Finally, to be stored in -80 DEG C of refrigerators spare by RNA.
3, the reverse transcription of LINC02327 RNA
Use the Reverse Transcriptase kit (D7170S) of the green skies Bioisystech Co., Ltd in Shanghai.Specific step is as follows:
(1) it removes genomic DNA: template Total RNA, 5 × gDNA Eraser Buffer is thawed on ice, 5 × RT
Buffer, 10 × RT Primer Mix, DEPC-treated Water thaw at (15-25 DEG C) of room temperature, are immediately placed in after defrosting
On ice.Every kind of solution is mixed before use and of short duration centrifugation is so that all liq is settled down to tube bottom.The denaturation of RNA, RNA sample
Product after thermal denaturation 5 minutes, are immediately placed in ice water cooling under the conditions of 65 DEG C.According to the form below ingredient is in the mixing of preparation reaction on ice
Then liquid is dispensed into each reaction tube again, is eventually adding RNA sample.Reaction system and condition are as shown in table 1.
Table 1
(2) in PCR instrument or in water-bath, 37 DEG C are incubated for 2 minutes.Be immediately placed in place on ice it is spare.
(3) reverse transcription system is prepared: being carried out reaction solution preparation on ice, is carried out reverse transcription reaction immediately after soft mixing.
Mixed liquor is prepared according to the reverse transcription reaction system of following table.Reaction system and condition are as shown in table 2.
Table 2
(4) 42 DEG C are incubated for 60 minutes to carry out reverse transcription reaction, and subsequent 80 DEG C of incubations are put in for 10 minutes after inactivation reverse transcriptase
On ice.Reverse transcription temperature can be improved to 50 DEG C, to enhance reverse transcription effect in complicated for secondary structure or high GC content template
Rate.
(5) cDNA obtained can immediately or -80 DEG C freeze after for subsequent real-time fluorescence quantitative PCR, cDNA was preferably avoided
More multigelations.
4, real-time quantitative PCR is carried out using the specific primer of LINC02327
Specific primer is synthesized in Sangon Biotech (Shanghai) Co., Ltd., including for detecting LINC02327 expression
Specific primer, primer sequence is the specific primer that SEQ NO:2 and SEQ NO:3 and reference gene TUBA1A are expressed,
Primer sequence is SEQ NO:4 and SEQ NO:5.The other reagents of real-time quantitative PCR utilize the green limited public affairs of skies biotechnology in Shanghai
The BeyoFast SYBR Green qPCR Mix (2 ×) of department, the specific steps are as follows:
(1) various solution needed for melting and mixing PCR reaction, BeyoFast SYBR Green qPCR Mix melt completely
And it mixes and is placed in ice chest.
(2) PCR reaction system (by taking 96 orifice plates as an example) are set on ice bath, reaction system and condition are as shown in table 3.
Table 3
| Reagent | Usage amount |
| BeyoFast™ SYBR Green qPCR Mix (2X, Low ROX) | 10μl |
| Specific primer (3 μM of concentration) | 2μl |
| Template DNA | 2μl |
| Water without RNA enzyme | 6μl |
| Total volume | 20μl |
(3) the usually amount of DNA profiling with 1-10ng cDNA is with reference to dosage, and final concentration of 0.2-0.5 μM of primer when can be obtained
Good detection effect is obtained, the final concentration of primer can also be according to circumstances adjusted.If it is necessary, gradient dilution can be carried out to template,
With the optimal template usage amount of determination.When the cDNA that reverse transcription PCR reacts is directly as template, additive amount is not exceeded
PCR reacts the 10% of total volume.The recommendation response system of 96 orifice plates is 20 μ l, can also be expanded in proportion according to actual experiment demand
Big or diminution reaction system.
(4) mixing is gently blown and beaten with pipettor or slight Vortex is mixed, and room temperature is centrifuged the several seconds, and liquid is made to accumulate in pipe
Bottom.
(5) the PCR reaction tube set or PCR reaction plate are placed on fluorescence quantitative PCR instrument, start PCR reaction.
(6) PCR response procedures: the initial denaturation of template is carried out before real-time fluorescence quantitative PCR reacts, is typically set at 95 DEG C
2 minutes.Using following PCR program, this program is by taking ABI 7900HT fluorescence quantitative PCR instrument as an example: a. initial denaturation: 95 DEG C
2min；B. it is denaturalized: 95 DEG C of 15sec；C. annealing/extension: 60 DEG C of 15-30sec；D. step b and step c is repeated, in total
40 circulations；E. melting curve analysis (optional): 95 DEG C of 15sec, 60 DEG C of 15sec, 95 DEG C of 15sec；F. using glimmering
The software that Fluorescent Quantitative PCR instrument provides analyzes result.Three-step approach need to only add 72 DEG C of 30sec of a step after annealing/extension, then weight
Multiple step b, c and it is increased the step for totally 40 circulations.
5, the data analysis of LINC02327 expression quantity
This experimental data is included in 60 colorectal cancer patients and its normal control tissue.The interpretation of result of real-time quantitative PCR uses phase
To quantitative approach, that is, 2^-△△CtMethod.It is specific as follows: firstly, all gene C t values that will once test are put in order, later with each
The Ct value of target gene LINC02327 in group tumor sample subtracts the Ct value of itself reference gene TUBA1A, and obtained number is just
It is △ Ct；Changing formula into is exactly: △ Ct=Ct(target gene LINC02327)-Ct(reference gene TUBA1A)；It then, will be each
The △ Ct of group each target gene of tumor sample LINC02327 is calculated.With the △ Ct of tumor tissues sample in this experiment
The △ Ct of normal control tissue group sample is subtracted, and opposite number is taken to all results simultaneously, the result which obtains is exactly-
△△Ct.Finally, p- △ △ Ct carries out 2 power operation, i.e. 2^-△△CtJust show that the multiple of expression quantity changes.In triplicate, sharp
It is examined with nonparametric t- for statistical analysis.As a result as shown in Figure 1, in the tumor tissues of colon cancer LINC02327 expression quantity
It is higher than normal control tissue, difference have statistical difference (p< 0.05).
By 60 colorectal cancer patients follow-up statistics being included in above-mentioned experiment, including patient's First episode when
Between, treatment condition, recurrence status and death time etc., follow up time is at least 12 months.In selected colorectal cancer patients,
The expression value for choosing fluorescence real-time quantitative PCR analysis is reference standard, and the corresponding normal tissue of acquired results compares, and is tied
Fruit is as shown in Figure 2.The patient that LINC02327 expression is higher than normal control tissue in tumor tissues is defined as LINC02327 high table
Up to group, remaining is low expression group.By Kaplan-Meier survival analysis, LINC02327 high expresses the life cycle ratio of patient
The patient of LINC02327 low expression group is substantially reduced, and prognosis is worse, difference have it is statistically significant (p< 0.05).Therefore,
LINC02327 can be used as the specificity molecular marker of colorectal cancer patients prognosis.
The above is the preferred embodiment of the present invention, it is noted that for those skilled in the art, this hair
It is bright to be not restricted to the described embodiments, under the premise of not departing from general idea of the present invention, several variations can also be made and changed
Into these also should be considered as protection scope of the present invention.
SEQUENCE LISTING
<110>the first affiliated hospital of Zhengzhou University
<120>the biomarker long-chain non-coding RNA LINC02327 and kit of colon cancer prognosis are predicted
<130> 1
<160> 5
<170> PatentIn version 3.5
<210> 1
<211> 1309
<212> DNA
<213>people
<400> 1
cctcagattc aaataccggt ttctagaatt atccaattag aggaagtagg gcctcttaaa 60
gaaacgcctg attctaggac cttcaaggag atggaacata actcttcctc agtccttaag 120
tgtgaactgt gcatagcgac ttcccttatt gatgttaatt ttgatccctt ggtccagatg 180
ttgtccagtc ctctactttc tggttactgt ttcccctcat gcagctaata ggcattctgt 240
agagaaacat ttaaaaacca tgtaaataac ctgcttttca ttaaaatttt gctcctacat 300
tcagcatcca ttgatgattc ttgtctgacc caatgcccag tatgagaccg acccaggtct 360
gccttaatat atataccgta atatatacct aacagttttt tttttttttt tgagagggag 420
tctcgctctg tcgcccaggc tggagtgcag tatcgcgata tcggttcgct gcaagctccg 480
cctcccgggg tcacgtcatt ctcctgcctc agcttccgga gcagctggga ctgctggcgc 540
ccgccactac gctcggctaa tttttttgtg tttttagtag agacgggctt tcaccgtgtt 600
ggcctagcgg ttctccaact cctgacctca tgatcccccc gcctcagcct cccaaagtgc 660
tgggattaca agcgtgagcc accgcgaccc gccaacactc ttgacaacag tgctgtgcta 720
agaacttggg ggacttcaaa aagttcacca gttcctgtgt ccatggtagg gtgaaaagat 780
tttctacatc tttccttgac tagaaacaga agtcctgaaa caagaatata acgtcaggag 840
gccagaggct ttgtcctgcc taatgtgtta tttccacact gaataaaagc acctgagtcc 900
tggtaagtgc tcatatgatt ggctcaataa aagaataata aatgaattgg aaagaggaga 960
cagtgaagga tataggagat gtacctgata gcaacttact gcctctcagc tcaaaattca 1020
cccttcaaaa ccttttctac accaatggat agaattcctg tcagcatttc tcttttacgt 1080
tgaacacaat gttaagcttc ctcagtgaag gaccctagat ggacattgca ggaagaaggg 1140
acttcccctg ttggacctag aggttgtacc agcattgtag gtgggaggac atccactggc 1200
tctttgcaat agccatgtgt ccataaagta tagtttctca gcaatctcat tgcccagtct 1260
aggcttggca atcaccctcc tgcagcctta tcaacacatt gctcgaggc 1309
<210> 2
<211> 20
<212> DNA
<213>artificial synthesized
<400> 2
cggttctcca actcctgacc 20
<210> 3
<211> 20
<212> DNA
<213>artificial synthesized
<400> 3
gggtccttca ctgaggaagc 20
<210> 4
<211> 20
<212> DNA
<213>artificial synthesized
<400> 4
tgttcactgg tacgttgggg 20
<210> 5
<211> 20
<212> DNA
<213>artificial synthesized
<400> 5
cagggaagca gtgatggagg 20
Claims (7)
1. the biomarker for predicting colon cancer prognosis is long-chain non-coding RNA LINC02327, the long-chain non-coding RNA
The nucleic acid sequence of LINC02327 is as shown in SEQ NO:1.
2. application of the biomarker as described in claim 1 in the preparation of preparation prediction colon cancer prognosis.
3. application as claimed in claim 2, it is characterised in that: the preparation of the prediction colon cancer prognosis is real time fluorescent quantitative
PCR detection kit.
4. for predicting the real-time fluorescence quantitative PCR detection kit of colon cancer prognosis, it is characterised in that: comprising for detecting mesh
Gene LINC02327 expression specific primer, primer sequence be SEQ NO:2 and SEQ NO:3.
5. as claimed in claim 4 for predicting the real-time fluorescence quantitative PCR detection kit of colon cancer prognosis, feature exists
In: the real-time fluorescence quantitative PCR detection kit includes the specific primer of reference gene TUBA1A expression, and primer sequence is
SEQ NO:4 and SEQ NO:5.
6. as claimed in claim 5 for predicting the real-time fluorescence quantitative PCR detection kit of colon cancer prognosis, feature exists
In: the kit includes real time fluorescent quantitative SYBR dyestuff, without the water of RNA enzyme.
7. as claimed in claim 6 for predicting the real-time fluorescence quantitative PCR detection kit of colon cancer prognosis, feature exists
In: real time fluorescent quantitative SYBR dyestuff, target gene LINC02327 specific primer, reference gene in the kit
TUBA1A specific primer, water without RNA enzyme volume ratio be 10:1:1:6.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810806682.3A CN108977537A (en) | 2018-07-20 | 2018-07-20 | Predict the biomarker long-chain non-coding RNA LINC02327 and kit of colon cancer prognosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810806682.3A CN108977537A (en) | 2018-07-20 | 2018-07-20 | Predict the biomarker long-chain non-coding RNA LINC02327 and kit of colon cancer prognosis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108977537A true CN108977537A (en) | 2018-12-11 |
Family
ID=64549457
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810806682.3A Withdrawn CN108977537A (en) | 2018-07-20 | 2018-07-20 | Predict the biomarker long-chain non-coding RNA LINC02327 and kit of colon cancer prognosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108977537A (en) |
-
2018
- 2018-07-20 CN CN201810806682.3A patent/CN108977537A/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2598659A2 (en) | Method for using gene expression to determine prognosis of prostate cancer | |
| CN110923322B (en) | Bladder cancer-associated DNA methylation biomarker combination and detection kit | |
| CN106755344A (en) | Molecular marked compound and its application for the diagnosis of cancer of pancreas clinical prognosis | |
| ES2914727T3 (en) | Algorithms and methods to evaluate late clinical criteria in prostate cancer | |
| CN106967719B (en) | Application of long-chain non-coding RNA as prostate cancer molecular marker | |
| CN107312851A (en) | Myocardial infarction biomarker miR 1283 | |
| CN108707664A (en) | A kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc-COX19-2 and its application | |
| CN110093418B (en) | piRNA-54265 detection kit for early screening, diagnosis, curative effect and prognosis evaluation of colorectal cancer | |
| CN108977537A (en) | Predict the biomarker long-chain non-coding RNA LINC02327 and kit of colon cancer prognosis | |
| CN108998519A (en) | Predict the biomarker long-chain non-coding RNA LINC02413 and kit of colon cancer prognosis | |
| CN109266742A (en) | Predict the biomarker long-chain non-coding RNA LINC02456 and kit of colon cancer prognosis | |
| CN108728547A (en) | Application, kit and the detection method of kidney prognosis novel molecular marker non-coding RNA LINC00158 | |
| CN108424965A (en) | A kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc-CRYBA4-23 and its application | |
| CN108642183A (en) | Application, kit and the detection method of kidney prognosis novel molecular marker non-coding RNA LINC00671 | |
| CN108531606A (en) | Application, kit and the detection method of kidney prognosis novel molecular marker non-coding RNA IFNG-AS1 | |
| CN108998521A (en) | Predict the biomarker long-chain non-coding RNA LINC01728 and kit of colon cancer prognosis | |
| CN109022576A (en) | Predict the biomarker long-chain non-coding RNA LINC02447 and kit of colon cancer prognosis | |
| CN108728548A (en) | Application, kit and the detection method of kidney prognosis novel molecular marker non-coding RNA LIFR-AS1 | |
| CN108424966A (en) | A kind of gastric cancer prognosis molecule marker non-coding RNA Lnc-CIT-1 and its application | |
| CN108753978A (en) | Application, kit and the detection method of lung cancer for prognosis novel molecular marker non-coding RNA LINC01124 | |
| CN108753960A (en) | A kind of gastric cancer prognosis molecule marker non-coding RNA Lnc-DENR-2 and its application | |
| CN108998522A (en) | Predict the biomarker long-chain non-coding RNA LINC01725 and kit of colon cancer prognosis | |
| CN108546760A (en) | A kind of cancer of pancreas prognosis molecule marker non-coding RNA Lnc-COL20A1-2 and its application | |
| CN108977536A (en) | Predict the biomarker long-chain non-coding RNA LINC01504 and kit of lung cancer for prognosis | |
| CN108753977A (en) | Application, kit and the detection method of lung cancer for prognosis novel molecular marker non-coding RNA LINC00958 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20181211 |
|
| WW01 | Invention patent application withdrawn after publication |